Biocryst files NDA for previously failed flu drug peramivir
By Catherine Shaffer
Friday, December 20, 2013
Biocryst Pharmaceuticals Inc. has snatched victory from the jaws of defeat with a new drug application (NDA) filing for intravenous perimavir, a drug that failed a Phase III influenza trial just over a year ago.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.